ClinicalTrials.gg
RecruitingNCT07549061Updated Nov 10, 2026

Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC

A Phase 2 interventional study of Vebreltinib and Chemotherapy in NSCLC (Advanced Non-small Cell Lung Cancer), sponsored by Shanghai Chest Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Shanghai Chest Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 10, 2026Now RecruitingSite recruiting status changed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 46 studies in Carcinoma, Non-Small-Cell Lung by Shanghai Chest Hospital — 25 open to participants now, 29 under way, 3 of them phase 3. Carcinoma, Non-Small-Cell Lung · Shanghai Chest Hospital.

Planned enrollment
33rd of 37
19 · median 89
Started
2026
with 5 others
Phase 2
14 of 46
5 open now
Primary completion
2027-09
later than 13 of 28 live
Registered
41st of 46
by date

Among the 46 studies in Carcinoma, Non-Small-Cell Lung by Shanghai Chest Hospital, this one is the 33rd largest by planned enrollment of the 37 interventional ones that give a count, is one of 6 that started in 2026, is one of 14 in phase 2, reaches primary completion later than 13 of the 28 other live ones, and was the 41st registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

25 of the 46 studies in Carcinoma, Non-Small-Cell Lung by Shanghai Chest Hospital are open now, in 1 country. Recruiting first, the newest first:

19 more — sign in →

By country, each count listing its studies:

All 25 open studies →

Where they have run

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Carcinoma, Non-Small-Cell Lung by Shanghai Chest Hospital, or all of them as a file.
02

Study summary

To explore the efficacy and safety of vebreltinib plus platinum-doublet chemotherapy as first-line therapy in patients with driver mutation-negative, MET-overexpressing, PD-L1 TPS \< 50%, locally advanced or metastatic NSCLC .

Read the detailed description

This is a prospective, open-label, single-arm, single-centre, exploratory phase II study. The study will use a Simon two-stage design that will enroll approximately 19 patients with treatment-naïve, locally advanced or metastatic NSCLC without actionable driver oncogene alterations, PD-L1 TPS \< 50% and with MET protein overexpression. MET overexpression is defined as moderate-to-strong (2+ or 3+) MET staining in ≥50% of viable tumour cells by immunohistochemistry (IHC). Eligible patients will receive vebreltinib (100 mg orally twice daily) combined with platinum-based doublet chemotherapy in 21-day cycles for up to four induction cycles. Specifically, patients with non-squamous histology will receive pemetrexed plus platinum, whereas those with squamous histology will receive gemcitabine or paclitaxel-based regimens plus platinum. This will be followed by maintenance vebreltinib plus pemetrexed in patients with non-squamous histology, whereas those with squamous histology will receive vebreltinib only until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-defined discontinuation criteria.The primary endpoint is objective response rate (ORR) according to RECIST version 1.1. Secondary endpoints include disease control rate, duration of response, progression-free survival, overall survival, and safety. Exploratory analyses will evaluate associations between MET IHC characteristics and clinical outcomes.

03

Conditions studied

  • NSCLC (Advanced Non-small Cell Lung Cancer)

Keywords

  • NSCLC
  • Vebreltinib
  • Met
  • Overexpression
04

Who can participate

The criteria were revised on the registry on Nov 10, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet all of the following inclusion criteria:

  1. Provide written before initiation of any study-specific procedure and be willing and able to comply with study procedures.
  2. Be aged ≥18 years.
  3. Have or cytologically confirmed NSCLC. (pathology reports from outside institutions are acceptable).
  4. Have newly diagnosed locally advanced or NSCLC that is not amenable to curative surgery or radiotherapy according to the AJCC 9th edition staging system.
  5. Have no prior systemic anticancer therapy for advanced or metastatic disease. Prior or adjuvant systemic therapy, definitive chemoradiotherapy or radiotherapy is permitted provided that treatment was completed ≥12 months before recurrence.
  6. Have an performance status of 0-2.
  7. Have no actionable driver oncogene alteration identified by tissue and/or blood-based molecular testing. At a minimum, testing must exclude EGFR sensitising mutations, ALK rearrangements, ROS1 rearrangements, RET fusions, NTRK fusions, KRAS G12C mutations, BRAF V600E mutations, MET exon 14 skipping alterations and other actionable alterations according to current clinical practice and locally available testing. Concurrent MET amplification is permitted provided that the tumour meets the prespecified MET protein overexpression criterion.
  8. Have MET protein overexpression, defined as moderate-to-strong (2+ or 3+) MET staining in ≥50% of viable tumour cells by IHC.
  9. Have a TPS \<50%
  10. Have an estimated of at least 3 months.
  11. Have at least one according to version 1.1.
  12. Have adequate organ function as defined by the following laboratory criteria:

1) ≥1.5 × 10⁹/L; 2) ≥90 g/L; 3) ≥75 × 10⁹/L; 4) total serum ≤1.5 × ; 5) and ALT ≤3 × ULN, or ≤5 × ULN in patients with liver metastases; 6) serum creatinine \<1.5 × ULN. 7) >50 mL/min, calculated using the Cockcroft-Gault formula.

13. Women of must have a negative pregnancy test within 7 days before the first dose and all participants of must agree to use effective from informed consent until 3 months after the last dose of study treatment.

Exclusion criteria

Exclusion criteria

Participants meeting any of the following criteria will be excluded from the study:

1. Central nervous system conditions

  1. Spinal cord compression or symptomatic, unstable requiring urgent local treatment
  2. Patients with symptomatic brain metastases may be eligible if definitive local treatment has been completed, therapy has been discontinued, and neurological status has remained stable for at least 2 weeks after completion of definitive treatment and corticosteroid therapy.
  3. Asymptomatic brain metastases may be permitted if, in the investigator's judgement, immediate local treatment is not clinically indicated.

2. Prior treatment and medication history

  1. Major surgery, including intrathoracic, intra-abdominal, or intrapelvic surgery, within 4 weeks before enrolment, or failure to recover adequately from the effects of previous surgery. Thoracoscopic and mediastinoscopy are not considered major surgery; patients may be enrolled ≥1 week after these procedures if adequately recovered.
  2. Treatment with traditional Chinese medicines or Chinese patent medicines with an antitumour indication within 1 week before the first dose of study treatment.
  3. Concomitant treatment with strong inducers or strong CYP3A4 inhibitors that cannot be discontinued for at least 1 week before initiation of study treatment and avoided during study treatment.
  4. Any prior systemic antitumour therapy for advanced or NSCLC, including chemotherapy, immunotherapy, biologic therapy, targeted therapy, or agents. For patients with recurrent disease, prior or adjuvant systemic therapy, or definitive radiotherapy or chemoradiotherapy, with or without immunotherapy, biologic therapy, or investigational agents, is permitted provided that treatment was completed ≥12 months before documented disease recurrence.
  5. Radiotherapy involving >30% of the bone marrow or radiotherapy with a large treatment field within 4 weeks before the first dose of vebreltinib.
  6. Use of any investigational drug within 2 weeks before the first dose of study treatment or concurrent participation in another interventional clinical trial.

3. Other Diagnosis of another malignancy requiring active treatment within the previous 3 years, except for completely resected basal cell carcinoma or squamous cell carcinoma of the skin, or completely resected carcinoma in situ without evidence of recurrence.

4. Active infection and pulmonary or gastrointestinal conditions

  1. Active infection requiring systemic anti-infective treatment within 2 weeks before the first dose of study treatment, including pneumonia.
  2. Active tuberculosis or other clinically significant uncontrolled infection.
  3. Active , , (HIV) infection, as defined by the following:

    • hepatitis B: positive hepatitis B surface antigen (HBsAg) with HBV DNA ≥500 IU/mL;
    • hepatitis C: positive HCV antibody with detectable HCV RNA;
    • HIV infection: positive HIV antibody;
  4. History of interstitial lung disease, drug-induced interstitial lung disease, or radiation pneumonitis requiring systemic corticosteroid treatment, or current active interstitial lung disease requiring treatment or clinical intervention.
  5. Active gastrointestinal disease or other conditions that may significantly affect the absorption, distribution, metabolism, or excretion of oral vebreltinib, including active ulcerative gastrointestinal lesions, uncontrolled nausea, vomiting or diarrhoea, clinically significant malabsorption syndrome, in·ability to swallow oral medication, or previous major gastrointestinal surgery that may affect drug absorption.

5. Known hypersensitivity to vebreltinib, platinum compounds, pemetrexed, gemcitabine, nab-paclitaxel, or any of their , where applicable to the planned treatment regimen.

6. Other serious medical conditions Any serious, uncontrolled, or clinically significant medical condition that, in the investigator's judgement, could increase the risk associated with study treatment, interfere with the interpretation of study results, compromise protocol compliance, or otherwise make the participant unsuitable for the study. This includes, but is not limited to, severe or uncontrolled psychiatric disorders, active primary immunodeficiency, or a history of allogeneic organ transplantation.

7. Pregnancy and lactation Pregnant or breastfeeding women, or women of who are unwilling or unable to use highly effective during the study treatment period and for 3 months after the last dose of study treatment.

8. Other conditions affecting study participation Any other condition or circumstance that, in the investigator's judgement, would make the participant unsuitable for study participation or would compromise participant safety, study compliance, or the integrity of study assessments.

Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (estimated)

Study arms

  • Experimental
    vebreltinib+ platinum-based chemotherapy

    Drug: Vebreltinib · Drug: Chemotherapy

Interventions

  • vebreltinib,100 mg,oral,bid

  • DrugChemotherapy

    Administered in accordance with the approved label

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    defined as the proportion of participants achieving a best overall response of complete response (CR) or partial response (PR) according to RECIST version 1.1.

    Time frame: up to 24 months

Secondary outcomes

  1. PFS

    defined as the time from the first administration of study treatment until radiographic disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first.

    Time frame: up to 24 months

  2. DCR

    defined as the proportion of patients achieving CR, PR, or stable disease (SD) as the best overall response according to RECIST version 1.1.

    Time frame: up to 24 months

  3. OS

    defined as the time from the first administration of study treatment until death from any cause.

    Time frame: From the date of first dose up to death from any cause

  4. AE

    Adverse event

    Time frame: From the date of first dose until death (up to 24 months)

07

Study locations

1 of 1 sites recruiting
  • 241 West Huaihai Road, Xuhui District, Shanghai, 200030, China.
    Shanghai, Shanghai Municipality, China
    Recruiting
    • Wei Nie, PhD · Contact021-22200000
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2027, 11 months after the start.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 11 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Mar 2026 → Sep 2026, primary completion May 2028 → Sep 2027 and completion Dec 2028 → Sep 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2026
First posted
Apr 23, 2026
StartActual
Sep 3, 2026was Mar 2026
Primary completionEst.
Sep 1, 2027was May 2028
CompletionEst.
Sep 1, 2028was Dec 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
241 West Huaihai Road, Xuhui District, Shanghai, 200030, China. is now Recruiting
Nov 10, 2026
Start date
Mar 30, 2026→Sep 3, 2026 (actual)
Nov 10, 2026
Primary completion
May 30, 2028→Sep 1, 2027
Nov 10, 2026
Study completion
Dec 30, 2028→Sep 1, 2028
Nov 10, 2026
Eligibility
5 inclusion criteria edited, 10 added, 7 removed; 9 exclusion criteria edited, 17 added, 16 removed
What changed in the criteria
Inclusion criteria
  • AddedPatients must meet all of the following inclusion criteria:
  • EditedVoluntarily sign aProvide written informed consent form (ICF) to participate in thebefore initiation of any study;-specific procedure and be willing and able to comply with study-related visits and procedures.
  • EditedMale or female subjectsBe aged ≥18 years or older.
  • RemovedPathologically confirmed non-small cell lung cancer (NSCLC); outside hospital pathology reports are acceptable.
  • RemovedNewly diagnosed metastatic NSCLC (clinical Stage IVA or IVB) or recurrent NSCLC (staged in accordance with the AJCC Cancer Staging Manual 9th edition), not eligible for curative-intent surgery or radiotherapy.
  • RemovedTreatment-naïve advanced NSCLC not amenable to curative surgery or radiotherapy. For recurrent disease, prior adjuvant and neoadjuvant therapy (chemotherapy, radiotherapy, immunotherapy, biologic therapy, investigational agents), or definitive radiotherapy/chemoradiotherapy with or without immunotherapy, biologic therapy, or investigational agents is permitted if completed at least 12 months before disease recurrence.
  • AddedHave histologically or cytologically confirmed NSCLC. (pathology reports from outside institutions are acceptable).
  • AddedHave newly diagnosed locally advanced or metastatic NSCLC that is not amenable to curative surgery or radiotherapy according to the AJCC 9th edition staging system.
  • AddedHave no prior systemic anticancer therapy for advanced or metastatic disease. Prior neoadjuvant or adjuvant systemic therapy, definitive chemoradiotherapy or radiotherapy is permitted provided that treatment was completed ≥12 months before recurrence.
  • EditedEastern Cooperative Oncology Group (Have an ECOG) performance status (PS) score of 0-2.
  • RemovedDriver gene-negative status confirmed by tumor tissue or blood sample, including but not limited to negative EGFR mutation, negative ALK rearrangement, negative ROS1 rearrangement, negative KRAS G12C mutation, and negative MET exon 14 skipping mutation. MET amplification is permitted: FISH demonstrating GCN ≥ 4 or MET/CEP7 ≥ 2, or positive result confirmed by NGS.
  • RemovedMET protein overexpression defined as ≥50% of tumor cells staining at IHC 2++ or stronger. Local laboratory IHC results are acceptable.
  • AddedHave no actionable driver oncogene alteration identified by tissue and/or blood-based molecular testing. At a minimum, testing must exclude EGFR sensitising mutations, ALK rearrangements, ROS1 rearrangements, RET fusions, NTRK fusions, KRAS G12C mutations, BRAF V600E mutations, MET exon 14 skipping alterations and other actionable alterations according to current clinical practice and locally available testing. Concurrent MET amplification is permitted provided that the tumour meets the prespecified MET protein overexpression criterion.
  • AddedHave MET protein overexpression, defined as moderate-to-strong (2+ or 3+) MET staining in ≥50% of viable tumour cells by IHC.
  • AddedHave a PD-L1 TPS <50%
  • EditedEstimated overall survivalHave an estimated life expectancy of at least 3 months.
  • RemovedLaboratory values meeting the following requirements:
  • AddedHave at least one measurable lesion according to RECIST version 1.1.
  • AddedHave adequate organ function as defined by the following laboratory criteria:
  • EditedAbsolute1) absolute neutrophil count (ANC)≥1.5 × 10⁹/L; Hemoglobin2) hemoglobin ≥90 g/L; Platelets3) platelets ≥75 × 10⁹/L; Serum4) total serum bilirubin ≤1.5 ×upper limit of normal ( ULN); Aspartate aminotransferase (5) AST) and alanine aminotransferase (ALT)ALT ≤3 × ULN; for, or ≤5 × ULN in patients with liver metastases, AST and ALT≤5×ULN; Serum6) serum creatinine <1.5 × ULN. Creatinine7) creatinine clearance (CrCl)>50 mL/min, calculated using the Cockcroft-Gault formula.
  • RemovedMales with reproductive potential and females of childbearing potential must agree to use highly effective contraception from signing informed consent until 3 months after the last dose of study drug. For females of childbearing potential, a serum pregnancy test must be negative within ≤7 days before the first dose of study drug.
  • Added13. Women of childbearing potential must have a negative pregnancy test within 7 days before the first dose and all participants of reproductive potential must agree to use effective contraception from informed consent until 3 months after the last dose of study treatment.
Exclusion criteria
  • RemovedSpinal cord compression. Symptomatic or unstable brain metastases, unless the patient has completed curative treatment, is not receiving corticosteroid therapy, and has maintained a stable neurological status for at least 2 weeks after completion of curative treatment and steroid therapy. Patients with asymptomatic brain metastases may be included if the investigator determines there is no immediate indication for curative treatment.
  • EditedMeetingParticipants meeting any of the following prior treatment history criteriacriteria will be excluded from the study:
  • Added1. Central nervous system conditions
  • AddedSpinal cord compression or symptomatic, unstable brain metastases requiring urgent local treatment
  • AddedPatients with symptomatic brain metastases may be eligible if definitive local treatment has been completed, corticosteroid therapy has been discontinued, and neurological status has remained stable for at least 2 weeks after completion of definitive treatment and corticosteroid therapy.
  • AddedAsymptomatic brain metastases may be permitted if, in the investigator's judgement, immediate local treatment is not clinically indicated.
  • Added2. Prior treatment and medication history
  • EditedMajor surgery (e.g.,, including intrathoracic, intra-abdominal, or intrapelvic surgery), within 4 weeks prior to enrollmentbefore enrolment, or failure to recover adequately from sidethe effects of suchprevious surgery. Thoracoscopic biopsy and mediastinoscopy are not considered major surgery, and; patients may be enrolled ≥1 week after these procedures if adequately recovered.
  • EditedTreatment with traditional Chinese medicine (TCM)medicines or Chinese patent medicinemedicines with anti-tumor indicationsan antitumour indication within 1 week prior tobefore the first dose of study drugtreatment.
  • EditedTreatmentConcomitant treatment with strong CYP3A4 inducers and/or strong CYP3A4 inhibitors, and inability to discontinue such agents that cannot be discontinued for at least 1 week prior tobefore initiation of study treatment and avoided during the study periodtreatment.
  • EditedPriorAny prior systemic anti-tumorantitumour therapy for advanced or metastatic NSCLC, including chemotherapy, biologic therapy, immunotherapy, or any investigational agent, administered as non-curative surgery or radiotherapy. For recurrent disease, prior adjuvant and neoadjuvant therapy (chemotherapy, radiotherapy, immunotherapy, biologic therapy, targeted therapy, or investigational agents). For patients with recurrent disease, prior neoadjuvant or adjuvant systemic therapy, or definitive radiotherapy/ or chemoradiotherapy, with or without immunotherapy, biologic therapy, or investigational agents, is permitted only ifprovided that treatment was completed at least ≥12 months before documented disease recurrence.
  • EditedRadiation therapy to more than Radiotherapy involving >30% of the bone marrow, or radiotherapy with a large- treatment field radiation therapy within 4 weeks prior tobefore the first dose of vebreltinib.
  • RemovedPatients with intracranial lesions requiring urgent local treatment for symptom relief are recommended for exclusion, at the discretion of the investigator.
  • RemovedAny severe or uncontrolled systemic disease, including but not limited to other severe medical or psychiatric disorders or laboratory abnormalities that, in the investigator's judgment, render the study drug inappropriate for the patient or impair compliance with the protocol.
  • RemovedMeeting any of the following cardiac function or disease criteria:
  • RemovedMean corrected QT interval (QTc) > 470 ms based on three routine ECG assessments performed at least 5 minutes apart (preferably completed within 1 hour) during the screening period at rest. Calculation shall be performed using the Fridericia formula (see Appendix 5 for details), with mean QTcF > 470 ms.
  • RemovedAny significant cardiac arrhythmia, such as complete left bundle branch block, second- or third-degree heart block, ventricular arrhythmia, drug-uncontrolled supraventricular or nodal arrhythmia, or other drug-uncontrolled cardiac arrhythmias.
  • RemovedAny risk factors for prolonged QTc interval, including chronic hypokalemia uncorrected by supplementation, congenital long QT syndrome, and concomitant use of QTc-prolonging medications.

…and 24 more changes, on the record history on ClinicalTrials.gov ↗

Nov 10, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionObjective Response Rate (ORR): how it is measured was reworded
Nov 10, 2026
Secondary outcomes
4 time frame changed, 3 description edited
What changed in the outcomes
  • Time framePFSFrom date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months → up to 24 months
  • Time frameDCREach 42 days up to intolerance the toxicity or PD (up to 24 months → up to 24 months
  • Time frameOSFrom randomization until death (up to 24 months) → From the date of first dose up to death from any cause
  • Time frameAEFrom randomization until death (up to 24 months) → From the date of first dose until death (up to 24 months)
  • DescriptionDCR: how it is measured was reworded
  • DescriptionOS: how it is measured was reworded
  • DescriptionPFS: how it is measured was reworded
Nov 10, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • 241 West Huaihai Road, Xuhui District, Shanghai, 200030, China. · Shanghai, ChinaContact added •••0000
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    241 West Huaihai Road, Xuhui District, Shanghai, 200030, China. is now Recruiting
    Start date Mar 30, 2026→Sep 3, 2026 (now actual)
    Primary completion May 30, 2028→Sep 1, 2027
    Study completion Dec 30, 2028→Sep 1, 2028
    Eligibility 5 inclusion criteria edited, 10 added, 7 removed; 9 exclusion criteria edited, 17 added, 16 removed
    What changed in the criteria
    Inclusion criteria
    • AddedPatients must meet all of the following inclusion criteria:
    • EditedVoluntarily sign aProvide written informed consent form (ICF) to participate in thebefore initiation of any study;-specific procedure and be willing and able to comply with study-related visits and procedures.
    • EditedMale or female subjectsBe aged ≥18 years or older.
    • RemovedPathologically confirmed non-small cell lung cancer (NSCLC); outside hospital pathology reports are acceptable.
    • RemovedNewly diagnosed metastatic NSCLC (clinical Stage IVA or IVB) or recurrent NSCLC (staged in accordance with the AJCC Cancer Staging Manual 9th edition), not eligible for curative-intent surgery or radiotherapy.
    • RemovedTreatment-naïve advanced NSCLC not amenable to curative surgery or radiotherapy. For recurrent disease, prior adjuvant and neoadjuvant therapy (chemotherapy, radiotherapy, immunotherapy, biologic therapy, investigational agents), or definitive radiotherapy/chemoradiotherapy with or without immunotherapy, biologic therapy, or investigational agents is permitted if completed at least 12 months before disease recurrence.
    • AddedHave histologically or cytologically confirmed NSCLC. (pathology reports from outside institutions are acceptable).
    • AddedHave newly diagnosed locally advanced or metastatic NSCLC that is not amenable to curative surgery or radiotherapy according to the AJCC 9th edition staging system.
    • AddedHave no prior systemic anticancer therapy for advanced or metastatic disease. Prior neoadjuvant or adjuvant systemic therapy, definitive chemoradiotherapy or radiotherapy is permitted provided that treatment was completed ≥12 months before recurrence.
    • EditedEastern Cooperative Oncology Group (Have an ECOG) performance status (PS) score of 0-2.
    • RemovedDriver gene-negative status confirmed by tumor tissue or blood sample, including but not limited to negative EGFR mutation, negative ALK rearrangement, negative ROS1 rearrangement, negative KRAS G12C mutation, and negative MET exon 14 skipping mutation. MET amplification is permitted: FISH demonstrating GCN ≥ 4 or MET/CEP7 ≥ 2, or positive result confirmed by NGS.
    • RemovedMET protein overexpression defined as ≥50% of tumor cells staining at IHC 2++ or stronger. Local laboratory IHC results are acceptable.
    • AddedHave no actionable driver oncogene alteration identified by tissue and/or blood-based molecular testing. At a minimum, testing must exclude EGFR sensitising mutations, ALK rearrangements, ROS1 rearrangements, RET fusions, NTRK fusions, KRAS G12C mutations, BRAF V600E mutations, MET exon 14 skipping alterations and other actionable alterations according to current clinical practice and locally available testing. Concurrent MET amplification is permitted provided that the tumour meets the prespecified MET protein overexpression criterion.
    • AddedHave MET protein overexpression, defined as moderate-to-strong (2+ or 3+) MET staining in ≥50% of viable tumour cells by IHC.
    • AddedHave a PD-L1 TPS <50%
    • EditedEstimated overall survivalHave an estimated life expectancy of at least 3 months.
    • RemovedLaboratory values meeting the following requirements:
    • AddedHave at least one measurable lesion according to RECIST version 1.1.
    • AddedHave adequate organ function as defined by the following laboratory criteria:
    • EditedAbsolute1) absolute neutrophil count (ANC)≥1.5 × 10⁹/L; Hemoglobin2) hemoglobin ≥90 g/L; Platelets3) platelets ≥75 × 10⁹/L; Serum4) total serum bilirubin ≤1.5 ×upper limit of normal ( ULN); Aspartate aminotransferase (5) AST) and alanine aminotransferase (ALT)ALT ≤3 × ULN; for, or ≤5 × ULN in patients with liver metastases, AST and ALT≤5×ULN; Serum6) serum creatinine <1.5 × ULN. Creatinine7) creatinine clearance (CrCl)>50 mL/min, calculated using the Cockcroft-Gault formula.
    • RemovedMales with reproductive potential and females of childbearing potential must agree to use highly effective contraception from signing informed consent until 3 months after the last dose of study drug. For females of childbearing potential, a serum pregnancy test must be negative within ≤7 days before the first dose of study drug.
    • Added13. Women of childbearing potential must have a negative pregnancy test within 7 days before the first dose and all participants of reproductive potential must agree to use effective contraception from informed consent until 3 months after the last dose of study treatment.
    Exclusion criteria
    • RemovedSpinal cord compression. Symptomatic or unstable brain metastases, unless the patient has completed curative treatment, is not receiving corticosteroid therapy, and has maintained a stable neurological status for at least 2 weeks after completion of curative treatment and steroid therapy. Patients with asymptomatic brain metastases may be included if the investigator determines there is no immediate indication for curative treatment.
    • EditedMeetingParticipants meeting any of the following prior treatment history criteriacriteria will be excluded from the study:
    • Added1. Central nervous system conditions
    • AddedSpinal cord compression or symptomatic, unstable brain metastases requiring urgent local treatment
    • AddedPatients with symptomatic brain metastases may be eligible if definitive local treatment has been completed, corticosteroid therapy has been discontinued, and neurological status has remained stable for at least 2 weeks after completion of definitive treatment and corticosteroid therapy.
    • AddedAsymptomatic brain metastases may be permitted if, in the investigator's judgement, immediate local treatment is not clinically indicated.
    • Added2. Prior treatment and medication history
    • EditedMajor surgery (e.g.,, including intrathoracic, intra-abdominal, or intrapelvic surgery), within 4 weeks prior to enrollmentbefore enrolment, or failure to recover adequately from sidethe effects of suchprevious surgery. Thoracoscopic biopsy and mediastinoscopy are not considered major surgery, and; patients may be enrolled ≥1 week after these procedures if adequately recovered.
    • EditedTreatment with traditional Chinese medicine (TCM)medicines or Chinese patent medicinemedicines with anti-tumor indicationsan antitumour indication within 1 week prior tobefore the first dose of study drugtreatment.
    • EditedTreatmentConcomitant treatment with strong CYP3A4 inducers and/or strong CYP3A4 inhibitors, and inability to discontinue such agents that cannot be discontinued for at least 1 week prior tobefore initiation of study treatment and avoided during the study periodtreatment.
    • EditedPriorAny prior systemic anti-tumorantitumour therapy for advanced or metastatic NSCLC, including chemotherapy, biologic therapy, immunotherapy, or any investigational agent, administered as non-curative surgery or radiotherapy. For recurrent disease, prior adjuvant and neoadjuvant therapy (chemotherapy, radiotherapy, immunotherapy, biologic therapy, targeted therapy, or investigational agents). For patients with recurrent disease, prior neoadjuvant or adjuvant systemic therapy, or definitive radiotherapy/ or chemoradiotherapy, with or without immunotherapy, biologic therapy, or investigational agents, is permitted only ifprovided that treatment was completed at least ≥12 months before documented disease recurrence.
    • EditedRadiation therapy to more than Radiotherapy involving >30% of the bone marrow, or radiotherapy with a large- treatment field radiation therapy within 4 weeks prior tobefore the first dose of vebreltinib.
    • RemovedPatients with intracranial lesions requiring urgent local treatment for symptom relief are recommended for exclusion, at the discretion of the investigator.
    • RemovedAny severe or uncontrolled systemic disease, including but not limited to other severe medical or psychiatric disorders or laboratory abnormalities that, in the investigator's judgment, render the study drug inappropriate for the patient or impair compliance with the protocol.
    • RemovedMeeting any of the following cardiac function or disease criteria:
    • RemovedMean corrected QT interval (QTc) > 470 ms based on three routine ECG assessments performed at least 5 minutes apart (preferably completed within 1 hour) during the screening period at rest. Calculation shall be performed using the Fridericia formula (see Appendix 5 for details), with mean QTcF > 470 ms.
    • RemovedAny significant cardiac arrhythmia, such as complete left bundle branch block, second- or third-degree heart block, ventricular arrhythmia, drug-uncontrolled supraventricular or nodal arrhythmia, or other drug-uncontrolled cardiac arrhythmias.
    • RemovedAny risk factors for prolonged QTc interval, including chronic hypokalemia uncorrected by supplementation, congenital long QT syndrome, and concomitant use of QTc-prolonging medications.

    …and 24 more changes, on the record history on ClinicalTrials.gov ↗

    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionObjective Response Rate (ORR): how it is measured was reworded
    Secondary outcomes 4 time frame changed, 3 description edited
    What changed in the outcomes
    • Time framePFSFrom date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months → up to 24 months
    • Time frameDCREach 42 days up to intolerance the toxicity or PD (up to 24 months → up to 24 months
    • Time frameOSFrom randomization until death (up to 24 months) → From the date of first dose up to death from any cause
    • Time frameAEFrom randomization until death (up to 24 months) → From the date of first dose until death (up to 24 months)
    • DescriptionDCR: how it is measured was reworded
    • DescriptionOS: how it is measured was reworded
    • DescriptionPFS: how it is measured was reworded
    Site contacts Changed at 1 site. See the sites
    Show the site
    • 241 West Huaihai Road, Xuhui District, Shanghai, 200030, China. · Shanghai, ChinaContact added •••0000
    + 7 other changes: index terms, identifiers, verification date, description, conditions, arm descriptions and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07549061
Responsible party
Hua Zhong (Shanghai Chest Hospital, Shanghai Chest Hospital of Shanghai Jiao Tong University) — Principal investigator
First posted
Apr 23, 2026
Start date
Sep 3, 2026
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Wei Nie
Contact
niewei-1001@163.com
021-63846590
Wei Nie
principal investigator · Shanghai Chest Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vebreltinib

Start the discussion